Pharmaceuticals, Biotechnology and Life Sciences
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of…
First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults…
Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on…
— Santiago Arroyo, M.D., Ph.D. joined as CMO on November 7, 2022 — — Jeff W. Jacobs, Ph.D. to join…
MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage…
Clinically significant and dose-dependent reduction in blood pressure with baxdrostat Highly selective mechanism of action with no meaningful impact on…
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions…
– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B…
Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral…
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients…